Table of Content

1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17

2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 27
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 37
2.4 Emerging Opportunities and Market Trends 40
2.5 Porter’s Fiver Forces Analysis 44

3 Segmentation of North America Market by Vaccine Type 48
3.1 Market Overview by Vaccine Type 48
3.2 Live/Attenuated Vaccines 50
3.3 Inactivated Vaccines 51
3.4 Subunit Vaccines 52
3.5 Toxoid Vaccines 53
3.6 Conjugate Vaccines 54
3.7 mRNA Vaccines 55
3.8 Recombinant Vector Vaccines 56
3.9 Other Vaccines 57

4 Segmentation of North America Market by Disease 58
4.1 Market Overview by Disease 58
4.2 Pneumococcal Disease 60
4.3 Poliovirus 61
4.4 Hepatitis 62
4.5 Influenza 63
4.6 Measles, Mumps, and Rubella (MMR) 64
4.7 Varicella 65
4.8 Human Papilloma Virus 66
4.9 COVID-19 67
4.10 Other Diseases 68

5 Segmentation of North America Market by Administration 69
5.1 Market Overview by Administration 69
5.2 Intramuscular Route 71
5.3 Subcutaneous Route 72
5.4 Oral Route 73
5.5 Intravenous Injection 74
5.6 Other Administration Routes 75

6 Segmentation of North America Market by Patient 76
6.1 Market Overview by Patient 76
6.2 Pediatric Vaccines 78
6.3 Adult Vaccines 80

7 North America Market 2022-2032 by Country 82
7.1 Overview of North America Market 82
7.2 U.S. 85
7.3 Canada 89
7.4 Mexico 92

8 Competitive Landscape 95
8.1 Overview of Key Vendors 95
8.2 New Product Launch, Partnership, Investment, and M&A 98
8.3 Company Profiles 99
AstraZeneca plc 99
Bavarian Nordic A/S 101
China National Biotec Group Company Ltd. 104
CSL Ltd. 106
Daiichi Sankyo Co. Ltd 108
Emergent BioSolutions Inc. 110
GlaxoSmithKline plc 112
Johnson & Johnson 116
Merck & Co. 118
Moderna Inc. 120
Novavax, Inc. 121
Pfizer Inc. 123
Sanofi SA 127
Takeda Pharmaceutical Co. Ltd. 130
RELATED REPORTS 132



List of Figures

List of Figures:

Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032 17
Figure 4. North America Preventive Vaccines Market, 2022-2032, $ mn 20
Figure 5. Development Stages of Preventive Vaccines 21
Figure 6. Impact of COVID-19 on Business 25
Figure 7. Primary Drivers and Impact Factors of North America Preventive Vaccines Market 31
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 34
Figure 9. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million 35
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 35
Figure 11. Primary Restraints and Impact Factors of North America Preventive Vaccines Market 37
Figure 12. Investment Opportunity Analysis 41
Figure 13. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market 44
Figure 14. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2022-2032, % of Revenue 49
Figure 15. North America Addressable Market Cap in 2023-2032 by Vaccine Type, Value ($ mn) and Share (%) 49
Figure 16. North America Preventive Vaccines Market by Vaccine Type: Live/Attenuated Vaccines, 2022-2032, $ mn 50
Figure 17. North America Preventive Vaccines Market by Vaccine Type: Inactivated Vaccines, 2022-2032, $ mn 51
Figure 18. North America Preventive Vaccines Market by Vaccine Type: Subunit Vaccines, 2022-2032, $ mn 52
Figure 19. North America Preventive Vaccines Market by Vaccine Type: Toxoid Vaccines, 2022-2032, $ mn 53
Figure 20. North America Preventive Vaccines Market by Vaccine Type: Conjugate Vaccines, 2022-2032, $ mn 54
Figure 21. North America Preventive Vaccines Market by Vaccine Type: mRNA Vaccines, 2022-2032, $ mn 55
Figure 22. North America Preventive Vaccines Market by Vaccine Type: Recombinant Vector Vaccines, 2022-2032, $ mn 56
Figure 23. North America Preventive Vaccines Market by Vaccine Type: Other Vaccines, 2022-2032, $ mn 57
Figure 24. Breakdown of North America Preventive Vaccines Market by Disease, 2022-2032, % of Sales Revenue 59
Figure 25. North America Addressable Market Cap in 2023-2032 by Disease, Value ($ mn) and Share (%) 59
Figure 26. North America Preventive Vaccines Market by Disease: Pneumococcal Disease, 2022-2032, $ mn 60
Figure 27. North America Preventive Vaccines Market by Disease: Poliovirus, 2022-2032, $ mn 61
Figure 28. North America Preventive Vaccines Market by Disease: Hepatitis, 2022-2032, $ mn 62
Figure 29. North America Preventive Vaccines Market by Disease: Influenza, 2022-2032, $ mn 63
Figure 30. North America Preventive Vaccines Market by Disease: Measles, Mumps, and Rubella (MMR), 2022-2032, $ mn 64
Figure 31. North America Preventive Vaccines Market by Disease: Varicella, 2022-2032, $ mn 65
Figure 32. North America Preventive Vaccines Market by Disease: Human Papilloma Virus, 2022-2032, $ mn 66
Figure 33. North America Preventive Vaccines Market by Disease: COVID-19, 2022-2032, $ mn 67
Figure 34. North America Preventive Vaccines Market by Disease: Other Diseases, 2022-2032, $ mn 68
Figure 35. Breakdown of North America Preventive Vaccines Market by Administration, 2022-2032, % of Sales Revenue 70
Figure 36. North America Addressable Market Cap in 2023-2032 by Administration, Value ($ mn) and Share (%) 70
Figure 37. North America Preventive Vaccines Market by Administration: Intramuscular Route, 2022-2032, $ mn 71
Figure 38. North America Preventive Vaccines Market by Administration: Subcutaneous Route, 2022-2032, $ mn 72
Figure 39. North America Preventive Vaccines Market by Administration: Oral Route, 2022-2032, $ mn 73
Figure 40. North America Preventive Vaccines Market by Administration: Intravenous Injection, 2022-2032, $ mn 74
Figure 41. North America Preventive Vaccines Market by Administration: Other Administration Routes, 2022-2032, $ mn 75
Figure 42. Breakdown of North America Preventive Vaccines Market by Patient, 2022-2032, % of Revenue 77
Figure 43. North America Addressable Market Cap in 2023-2032 by Patient, Value ($ mn) and Share (%) 77
Figure 44. North America Preventive Vaccines Market by Patient: Pediatric Vaccines, 2022-2032, $ mn 78
Figure 45. North America Preventive Vaccines Market by Patient: Adult Vaccines, 2022-2032, $ mn 80
Figure 46. Breakdown of North America Preventive Vaccines Market by Country, 2022 and 2032, % of Revenue 83
Figure 47. Contribution to North America 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 48. U.S. Preventive Vaccines Market, 2022-2032, $ mn 86
Figure 49. Canada Preventive Vaccines Market, 2022-2032, $ mn 89
Figure 50. Preventive Vaccines Market in Mexico, 2022-2032, $ mn 92
Figure 51. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period 95

List of Tables

List of Tables:

Table 1. Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2022-2032 18
Table 2. World Economic Outlook, 2021-2031 23
Table 3. World Economic Outlook, 2021-2023 24
Table 4. Scenarios for Economic Impact of Ukraine Crisis 28
Table 5. World Health Spending by Region, $ bn, 2013-2020 36
Table 6. Main Product Trends and Market Opportunities in North America Preventive Vaccines Market 40
Table 7. North America Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 48
Table 8. North America Preventive Vaccines Market by Disease, 2022-2032, $ mn 58
Table 9. North America Preventive Vaccines Market by Administration, 2022-2032, $ mn 69
Table 10. North America Preventive Vaccines Market by Patient, 2022-2032, $ mn 76
Table 11. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2022-2032, $ mn 79
Table 12. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2022-2032, $ mn 81
Table 13. North America Preventive Vaccines Market by Country, 2022-2032, $ mn 83
Table 14. U.S. Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 87
Table 15. U.S. Preventive Vaccines Market by Disease, 2022-2032, $ mn 87
Table 16. U.S. Preventive Vaccines Market by Administration, 2022-2032, $ mn 88
Table 17. Canada Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 90
Table 18. Canada Preventive Vaccines Market by Disease, 2022-2032, $ mn 90
Table 19. Canada Preventive Vaccines Market by Administration, 2022-2032, $ mn 91
Table 20. Mexico Preventive Vaccines Market by Vaccine Type, 2022-2032, $ mn 93
Table 21. Mexico Preventive Vaccines Market by Disease, 2022-2032, $ mn 93
Table 22. Mexico Preventive Vaccines Market by Administration, 2022-2032, $ mn 94
Table 23. AstraZeneca plc: Company Snapshot 99
Table 24. AstraZeneca plc: Business Segmentation 100
Table 25. AstraZeneca plc: Product Portfolio 100
Table 26. Bavarian Nordic A/S: Company Snapshot 101
Table 27. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 102
Table 28. China National Biotec Group Company Ltd.: Company Snapshot 104
Table 29. CSL Ltd.: Company Snapshot 106
Table 30. Daiichi Sankyo Co. Ltd.: Company Snapshot 108
Table 31. Emergent BioSolutions Inc.: Company Snapshot 110
Table 32. GlaxoSmithKline: Company Snapshot 112
Table 33. GlaxoSmithKline: Business Segmentation 113
Table 34. GlaxoSmithKline: Product Portfolio 114
Table 35. GlaxoSmithKline: Revenue, 2018-2020, $ bn 115
Table 36. GlaxoSmithKline: Recent Developments 115
Table 37. Johnson & Johnson: Company Snapshot 116
Table 38. Johnson & Johnson: Business Segments 117
Table 39. Merck & Co., Inc.: Company Snapshot 118
Table 40. Merck & Co., Inc.: Business Segmentation 118
Table 41. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 119
Table 42. Moderna Inc.: Company Snapshot 120
Table 43. Novavax, Inc.: Company Snapshot 121
Table 44. Pfizer Inc.: Company Snapshot 123
Table 45. Pfizer Inc.: Business Segmentation 124
Table 46. Pfizer Inc.: Product Portfolio 125
Table 47. Pfizer Inc.: Revenue, 2018-2020, $ bn 126
Table 48. Pfizer Inc.: Recent Developments 126
Table 49. Sanofi: Company Snapshot 127
Table 50. Sanofi: Business Segmentation 127
Table 51. Sanofi: Revenue, 2018-2020, $ bn 129
Table 52. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 130